

VOLUMEN 54

NUMERUS suppl 2

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2026

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Ivan Milas

Editors

Lidija Beketić-Orešković, Antonio Juretić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Martina Mikulandra – Radiation Oncology

Technical Editor

Stjepan Horvat

Editorial Board

Iva Andrašek, Gordana Brozović, Sanda Bubanović, Ljubica Luetić Cavor, Ljiljana Mayer, Aleksandar Milenović, Melita Perić Balja, Mario Puljiz, Snježana Ramić, Vesna Ramljak, Andrej Roth, Marija Skoko, Danko Velimir Vrdoljak, Tiha Vučemilo

Editorial Council

M. Ban (Split, Croatia), M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), D. Danolić (Zagreb, Croatia), N. Đaković (Zagreb, Croatia), M. Gamulin (Zagreb, Croatia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), D. Krleža (Dublin, Ireland), J. Koeva-Balabanova (Sofia, Bulgaria), D. La Forgia (Bari, Italy), A. Lancia (Pavia, Italy), A. Mrkonjić (Malmö, Sweden), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S.Ž. Pavletić (Bethesda, USA), I. Tomaš (Osijek, Croatia), S. Tomić (Split, Croatia), D. Vagić (Zagreb, Croatia), E. Vrdoljak (Split, Croatia), Ž. Vujašković (Baltimore, USA).

This journal is indexed or abstracted by:

**SCOPUS, DOAJ, HRČAK, Scilit Basel, CrossReff, Index Copernicus, Google Scholar,
ResearchGate, JournalsPedia**

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia

Phone (385 1) 37 83 522

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 10 €. Annual subscription rates in Croatia: 45 € + VAT for institutions, 21 € + VAT for individuals and 10 € + VAT for students, to be remitted with Hrvatska narodna banka, account HR12 1001 0051 8630 0016 0 Ref.No.HR65 7129-051-26395 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska narodna banka, IBAN: HR12 1001 0051 8630 0016 0 (Ref.No.HR65 7129-051-26395), BIC code: NBHRHR2XXXX (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb



CARDIO – ONCOLOGY 2026
Second Croatian Symposium
on Cardiovascular Toxicity of Oncology Therapy

15. 05. – 16. 05. 2026.

Hotel Westin, Dvorana Panorama, 17th floor,
Ulica Isidora Kršnjavoga 1, Zagreb

Supplement editor:

Ivo Darko Gabrić

Zagreb, Croatia

May, 2026

ORGANIZERS

Sestre milosrdnice University Hospital Center, Zagreb:
Department of Cardiovascular Diseases
University Hospital for Tumors
Department of Oncology and Nuclear Medicine Association Onkoput

UNDER THE AUSPICES OF:

Croatian Cardiac Society
Croatian Society of Internal Oncology
Faculty of Medicine, Catholic University of Croatia, Zagreb

SYMPOSIUM ORGANIZERS:

Ivo Darko Gabrić
Ljubica Vazdar

ORGANIZING COMMITTEE:

Ivo Darko Gabrić (president)
Ljubica Vazdar (president)

Marko Boban, Sandra Jakšić-Jurinjak, Krešimir Kordić, Nenad Lakušić, Ana Tečić Vuger, Petra Sertić, Lea Skorup Čutić, Ozren Vinter, Mihaela Trajbar

Symposium Faculties:

Nikola Bulj (president), Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Zdravko Babić**, Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Marko Boban**, Sestre milosrdnice University Hospital Center, Zagreb and School of Dental Medicine University of Osijek, Osijek · **Siniša Car**, Sestre milosrdnice University Hospital Center, Zagreb and School of Health Studies, Catholic University of Croatia, Zagreb · **Jasna Čerkez-Habek**, University Hospital Sveti Duh, Zagreb and School of Medicine, Catholic University of Croatia, Zagreb · **Natalija Dedić Plavetić**, University Hospital Center Zagreb, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Diana Delić-Brkljačić**, Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Ana Fröbe**, Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb and School of Dental Medicine, University of Zagreb, Zagreb · **Ivo Darko Gabrić**, Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, Catholic University of Croatia, Zagreb · **Edvard Galić**, University Hospital Sveti Duh, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Karlo Golubić**, Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, Catholic University of Croatia, Zagreb · **Sandra Jakšić-Jurinjak**, University Hospital Center Zagreb, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Marijana Jazvić**, Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb · **Marijana Knežević Pravaček**, Department of Cardiology, General Hospital "Dr. Josip Benčević", Slavonski Brod and Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia · **Goran Krstajić**, Polyclinic for Prevention of CV Diseases and Rehabilitation Srčana, Zagreb and School of Dental Medicine University of Osijek, Osijek · **Nenad Lakušić**, Special Hospital Krapinske Toplice, Krapinske Toplice and School of Dental Medicine University of Osijek, Osijek · **Ivo Planinc**, University Hospital Center Zagreb, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Danijel Planinc**, Poliklinika Došen, Zagreb · **Vjekoslav Radeljić**, Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Jasna Radić**, Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Robert Šeparović**, Division for Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Ana Tečić Vuger**, Division for Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center · **Matias Trbušić**, Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Ljubica Vazdar**, Division for Medical Oncology, University Hospital for Tumors, Sestre milosrdnic, University Hospital Center, Zagreb and School of Medicine, University of Zagreb, Zagreb · **Ozren Vinter**, Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, Catholic University of Croatia, Zagreb · **Mislav Vrsalović**, Sestre milosrdnice University Hospital Center, Zagreb and School of Medicine, University of Zagreb, Zagreb

CONTENTS

Chiara Ćelić Antibody–drug conjugates in breast cancer treatment: is there concern for cardiovascular health?	1
Marin Boban, Krešimir Crljenko, Helena Jerkić Capecitabine-triggered cardiomyopathy on a background of prior anthracycline exposure with reverse remodeling following early quadruple therapy	2
Marijana Knežević Praveček, Katica Cvitkušić Lukenda, Domagoj Vučić Cardiac rhythm disorders in cardio-oncology: risk stratification, monitoring and individualized management	3
Petra Sertić Cardiac safety of pembrolizumab-based neoadjuvant chemoimmunotherapy in early triple-negative breast cancer	5
Marko Boban Cardiac tissue analyzes using magnetic resonance imaging.	6
Krešimir Kordić Cardiovascular emergencies in cardio-oncology	7
Jelena Prošev Cardiovascular toxicity induced by vascular endothelial growth factor inhibitors	8
Marta Tučkar, Katarina Toljan, Matias Trbušić (mentor) Disseminated non-small cell lung carcinoma following cardiac transplantation	9
Ljubica Vazdar, Mihaela Trajbar Early cardiovascular toxicity: to continue or modify oncological treatment?	10
Andrija Matijević, Ivo Darko Gabrić, Matias Trbušić, Krešimir Kordić, Ozren Vinter, Matej Nedić Emerging cardiac risks of immunotherapy: case report on a checkpoint inhibitor-induced myocarditis	11
Helena Jerkić Hypertension in cancer patients	12
Josipa Josipović Is there such a thing as cardioneurotoxicity?	14

Jure Murgić	
Managing cardiovascular risk in prostate cancer treatment	15
Lea Skorup Ćutić, Koraljka Benko, Tihana Salopek, Tamara Hlača Caput, Laura Afrić	
Myocardial infarction with non-obstructive coronary arteries (minoca) during 5-fluorouracil infusion: a case report.	16
Ljubica Vazdar	
Nutritional strategies in the prevention and rehabilitation of cardiotoxicity	18
Petra Sertić	
Personalization of anthracycline and fluoropyrimidine use – who is at risk of cardiotoxicity?	19
Nenad Lakušić, Ivana Sopek Merkaš, Mateja Pracaić, Luka Lakušić	
Place and role of cardiac rehabilitation in cardio-oncology patients; cardio-oncology rehabilitation (core)	20
Ivo Darko Gabrić	
Prevention and therapy of early cardiovascular toxicity	21
Siniša Car	
QT interval assessment in CDK4/6 inhibitor ribociclib therapy – how important is it? .	22
Goran Krstačić, Antonija Krstačić	
Receptive music therapy and fractal chrome music therapy in cardio-oncology	23
Lana Maričić	
Reversible cardiotoxicity – when can we expect recovery?	25
Karlo Golubić	
Vascular toxicity of cancer therapy	26